NEO [NASD]
NeoGenomics, Inc.
Index- P/E- EPS (ttm)-0.33 Insider Own1.40% Shs Outstand123.63M Perf Week-13.62%
Market Cap981.72M Forward P/E- EPS next Y-0.54 Insider Trans-0.20% Shs Float121.37M Perf Month3.98%
Income-35.60M PEG- EPS next Q-0.22 Inst Own91.90% Short Float4.70% Perf Quarter-31.11%
Sales486.00M P/S2.02 EPS this Y-286.40% Inst Trans-5.24% Short Ratio2.34 Perf Half Y-75.49%
Book/sh8.70 P/B0.96 EPS next Y31.60% ROA-1.90% Target Price18.33 Perf Year-81.35%
Cash/sh4.10 P/C2.04 EPS next 5Y1.30% ROE-3.20% 52W Range6.85 - 54.74 Perf YTD-75.47%
Dividend- P/FCF- EPS past 5Y29.40% ROI-6.80% 52W High-84.71% Beta0.78
Dividend %- Quick Ratio7.60 Sales past 5Y15.90% Gross Margin37.80% 52W Low22.19% ATR0.64
Employees2000 Current Ratio7.90 Sales Q/Q1.50% Oper. Margin-32.00% RSI (14)49.14 Volatility6.36% 7.42%
OptionableYes Debt/Eq0.50 EPS Q/Q-110.00% Profit Margin-7.30% Rel Volume1.18 Prev Close8.15
ShortableYes LT Debt/Eq0.50 EarningsApr 27 BMO Payout- Avg Volume2.44M Price8.37
Recom2.00 SMA203.16% SMA50-5.01% SMA200-66.37% Volume2,879,850 Change2.70%
Jun-03-22Initiated Piper Sandler Overweight $13
Mar-29-22Downgrade Stephens Overweight → Equal-Weight $34 → $16
Mar-29-22Downgrade BofA Securities Buy → Neutral $25 → $18
Jan-18-22Resumed Stephens Overweight $40
Dec-16-21Initiated Cowen Outperform $42
Nov-05-21Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-14-21Upgrade Raymond James Mkt Perform → Outperform $53
Jun-03-21Initiated Goldman Buy $55
Feb-25-21Resumed Needham Buy $65
Feb-25-21Downgrade Raymond James Outperform → Mkt Perform
Jan-28-21Initiated Truist Buy $65
Dec-11-20Resumed BTIG Research Buy $60
Oct-28-20Reiterated Needham Buy $39 → $46
Sep-09-20Initiated Morgan Stanley Overweight $46
Aug-28-20Initiated Guggenheim Buy $46
Jul-29-20Reiterated Needham Buy $33 → $39
Jun-25-20Initiated BofA/Merrill Buy $34
Apr-21-20Resumed Stephens Overweight $33
Mar-02-20Resumed Craig Hallum Buy $38
Feb-28-20Upgrade First Analysis Sec Outperform → Strong Buy
Jun-27-22 08:33AM  
Jun-21-22 02:00AM  
Jun-20-22 07:39AM  
Jun-13-22 11:13AM  
Jun-03-22 04:05PM  
07:00AM  
May-16-22 07:00AM  
May-10-22 02:00AM  
May-09-22 07:00AM  
May-05-22 04:05PM  
06:53AM  
Apr-27-22 08:45AM  
07:00AM  
Apr-25-22 07:00AM  
Apr-20-22 03:01PM  
Apr-11-22 10:00AM  
07:00AM  
Apr-08-22 04:05PM  
07:23AM  
Mar-30-22 07:21AM  
Mar-29-22 04:14PM  
Mar-28-22 04:58PM  
04:05PM  
07:00AM  
Mar-17-22 03:00AM  
Mar-02-22 04:05PM  
Feb-27-22 10:59PM  
Feb-23-22 08:45AM  
07:00AM  
Feb-14-22 07:00AM  
Feb-11-22 02:00AM  
Feb-08-22 07:00AM  
Feb-04-22 07:56AM  
Feb-03-22 05:38PM  
Feb-02-22 04:05PM  
01:38PM  
Feb-01-22 01:38PM  
01:38PM  
Jan-24-22 07:00AM  
Jan-11-22 07:00AM  
Dec-29-21 03:58PM  
Dec-13-21 02:00AM  
Dec-11-21 06:38AM  
06:38AM  
Dec-10-21 07:00AM  
Dec-07-21 12:15AM  
Nov-30-21 07:00AM  
05:00AM  
Nov-23-21 11:11AM  
Nov-10-21 07:00AM  
Nov-08-21 05:00AM  
Nov-06-21 01:30PM  
Nov-04-21 10:55AM  
07:02AM  
07:00AM  
Oct-28-21 03:05PM  
Oct-19-21 02:00AM  
Oct-13-21 04:20PM  
Oct-12-21 04:05PM  
Oct-01-21 01:13PM  
09:40AM  
Sep-09-21 07:00AM  
Sep-06-21 01:14PM  
Sep-01-21 04:05PM  
Aug-23-21 08:56AM  
Aug-13-21 12:53PM  
Aug-06-21 05:30PM  
10:55AM  
07:00AM  
Jul-30-21 03:00PM  
06:20AM  
Jul-14-21 04:05PM  
04:43AM  
Jun-21-21 08:04AM  
06:54AM  
Jun-18-21 10:34PM  
07:30AM  
Jun-08-21 08:01AM  
May-27-21 04:05PM  
May-25-21 04:44AM  
May-18-21 12:33PM  
May-12-21 09:02AM  
May-11-21 09:11AM  
May-10-21 04:15PM  
May-09-21 08:30AM  
May-05-21 06:01PM  
09:35AM  
08:38AM  
07:34AM  
07:00AM  
06:45AM  
12:00AM  
Apr-28-21 12:34PM  
Apr-19-21 07:00AM  
Apr-16-21 05:15AM  
Apr-13-21 07:00AM  
Apr-07-21 04:05PM  
Apr-01-21 06:05AM  
Mar-24-21 10:04AM  
08:59AM  
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TETRAULT LYNN A.DirectorMay 18Option Exercise7.273,33424,23839,111May 20 05:08 PM
Bonello WilliamChief Financial OfficerApr 28Option Exercise7.525,72743,067191,548May 02 05:46 PM
Bonello WilliamChief Financial OfficerMar 08Option Exercise7.525,00037,600103,516Mar 09 06:02 PM
Bonello WilliamChief Financial OfficerMar 07Sale18.293,20958,69398,516Mar 09 06:02 PM
McKenzie Kathryn BChief Sustainability/Risk OfcrJan 11Option Exercise9.072,10019,04749,361Jan 12 06:50 PM
Johnson Kevin CDirectorDec 22Option Exercise7.273,33424,23837,398Dec 23 05:25 PM
McKenzie Kathryn BChief Financial OfficerDec 22Option Exercise9.075,00045,35016,689Dec 23 05:25 PM
McKenzie Kathryn BChief Financial OfficerDec 21Sale35.001,84664,61011,689Dec 23 05:25 PM
Mallon MarkChief Executive OfficerDec 06Buy30.6317,000520,71072,736Dec 06 04:16 PM
Bonello WilliamPresident, InformaticsNov 30Option Exercise7.5225,000188,00040,473Dec 02 06:09 PM
Brown Douglas MatthewChief Strategy OfficerNov 26Sale36.8533,3341,228,35811,644Nov 26 04:14 PM
Bonello WilliamPresident, InformaticsNov 24Option Exercise8.0325,000200,75040,473Nov 29 04:16 PM
Bonello WilliamPresident, InformaticsNov 24Sale37.1325,000928,25015,473Nov 29 04:16 PM
Brown Douglas MatthewChief Strategy OfficerNov 24Sale36.8433,3331,227,98844,978Nov 26 04:14 PM
Brown Douglas MatthewChief Strategy OfficerNov 23Sale37.1933,3331,239,65478,311Nov 26 04:14 PM